Luhan Pharmachem Co., Ltd.
On January 12, 2018, the Food and Drug Administration granted regularapproval to olaparib tablets (Lynparza, AstraZ 01-26
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC 01-26
The U S Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include t 01-15
FDA permits marketing of device to treat diabetic foot ulcers01-03
On December 20, 2017, the Food and Drug Administration granted regular approval to pertuzumab (PERJETA, Genentech, 12-29
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome12-18
FDA approves Admelog, the first short-acting "follow-on " insulin product to treat diabetes12-13
On November 16, 2017, the Food and Drug Administration approved sunitinib malate (Sutent, Pfizer Inc ) for the ad 12-12
On November 16, 2017, the Food and Drug Administration granted regular approval to obinutuzumab (GAZYVA, Genentech, 12-08
FDA approves first biosimilar for the treatment of certain breast and stomach cancersThe U S Food and Drug Admin 12-06
FDA approves adjuvant treatment for adult patients at a high risk of kidney cancer returning after nephrectomy 11-20
Tel: +86 0871 6511 0906 (GMT+8 AM9:00-AM:12:00 PM1:30-PM6:00)
cell phone:188 1221 6310
Fax:0871-63602606
Email: info@luhancn.com
Address:Room 3301,33rd Floor Building B, Vogue Garden Plaza, No.1004 Beijing Road, Kunming, Yunnan Province, P. R. China 650000